Baseline characteristics and patient reported outcome data of patients prescribed etanercept: web-based and telephone evaluation

Table 4 Number (%) of patients with prior treatment of a biologic agent

	Rheumatoid arthritis	Ankylosing spondylitis	Psoriatic arthritis	Psoriasis	Other ^a	Total
N [N missing]	188 [3]	43 [0]	44 [0]	35 [0]	19 [12]	329 [15]
No prior treatment	127 (67.6%)	28 (65.1%)	30 (68.2%)	24 (68.6%)	15 (78.9%)	224 (68.1%)
Unsure of prior treatment	24 (12.8%)	5 (11.6%)	6 (13.6%)	4 (11.4%)	1 (5.3%)	40 (12.2%)
Any prior treatment	37 (19.7%)	10 (23.3%)	8 (18.2%)	7 (20.0%)	3 (15.8%)	65 (19.8%)
Adalimumab	31 (16.5%)	5 (11.6%)	7 (15.9%)	2 (5.7%)	3 (15.8%)	48 (14.6%)
Infliximab	7 (3.7%)	4 (9.3%)	0 (0.0%)	1 (2.9%)	0 (0.0%)	12 (3.6%)
Anakinra	2 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.6%)
Abatacept	0 (0.0%)	1 (2.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.3%)
Rituximab	3 (1.6%)	1 (2.3%)	1 (2.3%)	0 (0.0%)	0 (0.0%)	5 (1.5%)
Efalizumab	1 (0.5%)	0 (0.0%)	0 (0.0%)	4 (11.4%)	0 (0.0%)	5 (1.5%)

^a Includes patients with juvenile idiopathic arthritis (n = 9, 2.6%), patients responding other or not sure of condition (n = 10, 2.9%) and patients with condition missing (n = 12, 3.5%) to the question 'What condition do you have that is being treated with Enbrel?'

ISSN: 1471-2288